相容性建模辅助下紫杉醇负载PLGA纳米颗粒的设计。

IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Alžběta Zemánková , Anton Iemtsev , Martin Dinh , Alma Lucia Villela Zumaya , Vladimíra Svobodová Pavlíčková , Silvie Rimpelová , Barbora Vokatá , Fatima Hassouna , Michal Fulem
{"title":"相容性建模辅助下紫杉醇负载PLGA纳米颗粒的设计。","authors":"Alžběta Zemánková ,&nbsp;Anton Iemtsev ,&nbsp;Martin Dinh ,&nbsp;Alma Lucia Villela Zumaya ,&nbsp;Vladimíra Svobodová Pavlíčková ,&nbsp;Silvie Rimpelová ,&nbsp;Barbora Vokatá ,&nbsp;Fatima Hassouna ,&nbsp;Michal Fulem","doi":"10.1016/j.ijpharm.2025.125985","DOIUrl":null,"url":null,"abstract":"<div><div>Many anticancer active pharmaceutical ingredients (APIs), such as paclitaxel (PTX), exhibit poor water solubility, which limits their bioavailability and necessitates the use of excipients. While biodegradable polymeric excipients combined with nanotechnology offer promising solutions, the high cost of polymers and APIs, along with the vast number of potential API–polymer combinations, poses significant challenges in developing effective drug delivery systems (DDS). This study explores the potential of API–polymer phase behavior modeling as part of the design of nanoparticle (NP)-based DDS for PTX using poly(lactide-<em>co</em>-glycolide) (PLGA) and poly(lactide-<em>co</em>-glycolide)-b-poly(ethylene glycol) (PLGA-PEG) with varying molecular weights. The phase behavior of PTX–PLGA/PLGA-PEG systems, which reflects the compatibility of PTX with polymeric excipients, was predicted using the Conductor-like Screening Model for Real Solvents (COSMO-RS). To investigate the correlation between the predictions and experimental observations, PTX–PLGA and PEGylated PLGA NPs were prepared via an emulsion-solvent evaporation method with varying initial PTX amounts. The predicted trends in PTX solubility in polymeric excipients were then compared with key NP characteristics, such as drug loading, solid-state properties, and cytotoxicity in HeLa, SKOV-3, and MRC-5 cells. COSMO-RS predictions indicated limited PTX solubility in PLGA, which aligns with experimental observations, where the maximum amorphous PTX loading did not exceed 2 wt%, regardless of the polymer molecular weight. COSMO-RS modeling predicted higher compatibility of PTX with PEG, suggesting that incorporating PEG would enhance PTX loading in PEGylated NPs. This trend was corroborated by experimental findings, which showed increased drug loading capacity and slower PTX release from PEGylated NPs during cytotoxicity studies. These results highlight the potential of API–polymer modeling as a tool for tailoring polymeric carriers and optimizing API consumption in NP-based DDS development.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"682 ","pages":"Article 125985"},"PeriodicalIF":5.3000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design of paclitaxel-loaded PLGA nanoparticles assisted by compatibility modeling\",\"authors\":\"Alžběta Zemánková ,&nbsp;Anton Iemtsev ,&nbsp;Martin Dinh ,&nbsp;Alma Lucia Villela Zumaya ,&nbsp;Vladimíra Svobodová Pavlíčková ,&nbsp;Silvie Rimpelová ,&nbsp;Barbora Vokatá ,&nbsp;Fatima Hassouna ,&nbsp;Michal Fulem\",\"doi\":\"10.1016/j.ijpharm.2025.125985\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Many anticancer active pharmaceutical ingredients (APIs), such as paclitaxel (PTX), exhibit poor water solubility, which limits their bioavailability and necessitates the use of excipients. While biodegradable polymeric excipients combined with nanotechnology offer promising solutions, the high cost of polymers and APIs, along with the vast number of potential API–polymer combinations, poses significant challenges in developing effective drug delivery systems (DDS). This study explores the potential of API–polymer phase behavior modeling as part of the design of nanoparticle (NP)-based DDS for PTX using poly(lactide-<em>co</em>-glycolide) (PLGA) and poly(lactide-<em>co</em>-glycolide)-b-poly(ethylene glycol) (PLGA-PEG) with varying molecular weights. The phase behavior of PTX–PLGA/PLGA-PEG systems, which reflects the compatibility of PTX with polymeric excipients, was predicted using the Conductor-like Screening Model for Real Solvents (COSMO-RS). To investigate the correlation between the predictions and experimental observations, PTX–PLGA and PEGylated PLGA NPs were prepared via an emulsion-solvent evaporation method with varying initial PTX amounts. The predicted trends in PTX solubility in polymeric excipients were then compared with key NP characteristics, such as drug loading, solid-state properties, and cytotoxicity in HeLa, SKOV-3, and MRC-5 cells. COSMO-RS predictions indicated limited PTX solubility in PLGA, which aligns with experimental observations, where the maximum amorphous PTX loading did not exceed 2 wt%, regardless of the polymer molecular weight. COSMO-RS modeling predicted higher compatibility of PTX with PEG, suggesting that incorporating PEG would enhance PTX loading in PEGylated NPs. This trend was corroborated by experimental findings, which showed increased drug loading capacity and slower PTX release from PEGylated NPs during cytotoxicity studies. These results highlight the potential of API–polymer modeling as a tool for tailoring polymeric carriers and optimizing API consumption in NP-based DDS development.</div></div>\",\"PeriodicalId\":14187,\"journal\":{\"name\":\"International Journal of Pharmaceutics\",\"volume\":\"682 \",\"pages\":\"Article 125985\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0378517325008221\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378517325008221","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

许多抗癌活性药物成分(api),如紫杉醇(PTX),表现出较差的水溶性,这限制了它们的生物利用度,需要使用赋形剂。虽然生物可降解聚合物赋形剂与纳米技术相结合提供了有希望的解决方案,但聚合物和原料药的高成本,以及大量潜在的api -聚合物组合,对开发有效的药物输送系统(DDS)提出了重大挑战。本研究探索了api -聚合物相行为建模的潜力,作为设计基于纳米颗粒(NP)的PTX DDS的一部分,该DDS使用不同分子量的聚(丙交酯-共乙醇酸酯)(PLGA)和聚(丙交酯-共乙醇酸酯)-b-聚乙二醇(PLGA- peg)。利用真实溶剂类导体筛选模型(cosmos - rs)预测了PTX- plga /PLGA-PEG体系的相行为,反映了PTX与聚合物赋形剂的相容性。为了研究预测结果与实验结果之间的相关性,在不同初始PTX量的条件下,通过乳液-溶剂蒸发法制备了PTX-PLGA和聚乙二醇化PLGA NPs。然后将PTX在聚合物赋形剂中的溶解度预测趋势与关键NP特征(如HeLa、SKOV-3和MRC-5细胞中的药物负载、固态特性和细胞毒性)进行比较。cosmos - rs预测表明PTX在PLGA中的溶解度有限,这与实验观察结果一致,无论聚合物分子量如何,PTX的最大无定形负载不超过2 wt%。cosmos - rs模型预测PTX与PEG的相容性更高,这表明加入PEG可以增强PTX在聚乙二醇化NPs中的负载。实验结果证实了这一趋势,在细胞毒性研究中,聚乙二醇化NPs的载药量增加,PTX释放减慢。这些结果突出了API-聚合物建模作为定制聚合物载体和优化基于np的DDS开发中API消耗的工具的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Design of paclitaxel-loaded PLGA nanoparticles assisted by compatibility modeling

Design of paclitaxel-loaded PLGA nanoparticles assisted by compatibility modeling
Many anticancer active pharmaceutical ingredients (APIs), such as paclitaxel (PTX), exhibit poor water solubility, which limits their bioavailability and necessitates the use of excipients. While biodegradable polymeric excipients combined with nanotechnology offer promising solutions, the high cost of polymers and APIs, along with the vast number of potential API–polymer combinations, poses significant challenges in developing effective drug delivery systems (DDS). This study explores the potential of API–polymer phase behavior modeling as part of the design of nanoparticle (NP)-based DDS for PTX using poly(lactide-co-glycolide) (PLGA) and poly(lactide-co-glycolide)-b-poly(ethylene glycol) (PLGA-PEG) with varying molecular weights. The phase behavior of PTX–PLGA/PLGA-PEG systems, which reflects the compatibility of PTX with polymeric excipients, was predicted using the Conductor-like Screening Model for Real Solvents (COSMO-RS). To investigate the correlation between the predictions and experimental observations, PTX–PLGA and PEGylated PLGA NPs were prepared via an emulsion-solvent evaporation method with varying initial PTX amounts. The predicted trends in PTX solubility in polymeric excipients were then compared with key NP characteristics, such as drug loading, solid-state properties, and cytotoxicity in HeLa, SKOV-3, and MRC-5 cells. COSMO-RS predictions indicated limited PTX solubility in PLGA, which aligns with experimental observations, where the maximum amorphous PTX loading did not exceed 2 wt%, regardless of the polymer molecular weight. COSMO-RS modeling predicted higher compatibility of PTX with PEG, suggesting that incorporating PEG would enhance PTX loading in PEGylated NPs. This trend was corroborated by experimental findings, which showed increased drug loading capacity and slower PTX release from PEGylated NPs during cytotoxicity studies. These results highlight the potential of API–polymer modeling as a tool for tailoring polymeric carriers and optimizing API consumption in NP-based DDS development.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.70
自引率
8.60%
发文量
951
审稿时长
72 days
期刊介绍: The International Journal of Pharmaceutics is the third most cited journal in the "Pharmacy & Pharmacology" category out of 366 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信